Incyte (INCY) Tops Q2 EPS by 5c
Tweet
Share
E-mail
Get Alerts INCY Hot Sheet
Revenue Growth %: +31.3%
Financial Fact:
Income (loss) from operations: 22.29M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Incyte (NASDAQ: INCY) reported Q2 EPS of $0.80, $0.05 better than the analyst estimate of $0.75. Revenue for the quarter came in at $705.7 million versus the consensus estimate of $686.98 million.
Guidance:
|
| |
| Current | Previous |
Jakafi net product revenues | $2,125 - $2,170 million | $2,125 - $2,200 million |
Other Hematology/Oncology net product revenues | $155 - $170 million | $145 - $160 million |
GAAP Cost of product revenues | 6 – 7% of net product revenues | Unchanged |
Non-GAAP Cost of product revenues1 | 5 – 6% of net product revenues | Unchanged |
GAAP Research and development expenses | $1,350 - $1,390 million | Unchanged |
Non-GAAP Research and development expenses2 | $1,220 - $1,250 million | Unchanged |
GAAP Selling, general and administrative expenses | $725 - $755 million | $735 - $775 million |
Non-GAAP Selling, general and administrative expenses3 | $655 - $680 million | $665 - $700 million |
For earnings history and earnings-related data on Incyte (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Freedom Broker Starts Unity Bancorp (UNTY) at Hold
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
